DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma April 16, 2015 • 8:05 AM EDT
DelMar Pharmaceuticals Announces Panel Participation in Cancer Advance Boston Conference on April 14, 2015 April 7, 2015 • 8:00 AM EDT
DelMar Pharmaceuticals Appoints Biopharmaceutical Industry Veteran, Erich Mohr, Ph.D., R.Psych., to the Board of Directors April 1, 2015 • 8:05 AM EDT
DelMar Pharmaceuticals to Present at the 27th Annual ROTH Conference on March 10, 2015 March 3, 2015 • 8:00 AM EST
DelMar Pharmaceuticals Receives Notice of Allowance of Fourth U.S. Patent Covering Methods of Use and Compositions for VAL-083 March 2, 2015 • 11:17 AM EST
DelMar Pharmaceuticals to Present Clinical and Preclinical Abstracts for VAL-083 at the American Association of Cancer Research (AACR) Annual Meeting in April 2015 February 24, 2015 • 8:00 AM EST
DelMar Pharmaceuticals Announces December 31, 2014 Financial Results and Provides Corporate Update February 12, 2015 • 8:00 AM EST
DelMar Pharmaceuticals Appoints Lynda Cranston, BScN, MScN, ICD.D, to the Board of Directors February 11, 2015 • 8:13 AM EST
DelMar Pharmaceuticals Completes Offer to Exchange Common Stock for Outstanding Warrants February 10, 2015 • 9:35 AM EST
DelMar Pharmaceuticals Receives Notice of Allowance for Third US Patent for VAL-083 January 13, 2015 • 8:00 AM EST